학술논문
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
Document Type
Academic Journal
Author
Zen, Margherita; Gatto, Mariele; Depascale, Roberto; Regola, Francesca; Fredi, Micaela; Andreoli, Laura; Franceschini, Franco; Urban, Maria Letizia; Emmi, Giacomo; Ceccarelli, Fulvia; Conti, Fabrizio; Bortoluzzi, Alessandra; Govoni, Marcello; Tani, Chiara; Mosca, Marta; Ubiali, Tania; Gerosa, Maria; Bozzolo, Enrica P.; Canti, Valentina; Cardinaletti, Paolo; Gabrielli, Armando; Tanti, Giacomo; Gremese, Elisa; De Marchi, Ginevra; De Vita, Salvatore; Fasano, Serena; Ciccia, Francesco; Pazzola, Giulia; Salvarani, Carlo; Negrini, Simone; Di Matteo, Andrea; De Angelis, Rossella; Orsolini, Giovanni; Rossini, Maurizio; Faggioli, Paola; Laria, Antonella; Piga, Matteo; Cauli, Alberto; Scarpato, Salvatore; Rossi, Francesca Wanda; De Paulis, Amato; Brunetta, Enrico; Ceribelli, Angela; Selmi, Carlo; Prete, Marcella; Racanelli, Vito; Vacca, Angelo; Bartoloni, Elena; Gerli, Roberto; Zanatta, Elisabetta; Larosa, Maddalena; Saccon, Francesca; Doria, Andrea; Iaccarino, Luca
Source
Journal of Personalized Medicine. April 2023, Vol. 13 Issue 4
Subject
Language
English
ISSN
2075-4426
Abstract
Author(s): Margherita Zen [1]; Mariele Gatto [1]; Roberto Depascale [1]; Francesca Regola [2]; Micaela Fredi [2]; Laura Andreoli [2]; Franco Franceschini [2]; Maria Letizia Urban [3]; Giacomo Emmi [3]; Fulvia [...]
Aim. To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods. All patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (
Aim. To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods. All patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (